FLT3 and leukemia: In conclusion, FLT3 ligand-based CAR-T cells exhibited specific cytotoxicity against FLT3+ leukemia cell and had the ability to distinguish between FLT3 wild-type cells and FLT3-ITD mutant cells, which may be an ideal candidate that specifically target AML with FLT3 mutation.